NCT06280508

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

A Prospective, Single-arm Exploratory Trail of Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.

Conditions

• Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

Interventions

Type	Name	Description
DRUG	Adebrelimab, Apatinib, Gemcitabine, cisplatin	Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery

Timeline

• Start date: 2024-03-01
• Primary completion: 2027-03-31
• Completion: 2028-03-31
• First posted: 2024-02-28
• Last updated: 2024-04-23

Locations

1 site across 1 country: China